Three patients with pseudohypoaldosteronism type II carrying different mutant genes and exhibiting clinical heterogeneity all responded to hydrochlorothiazide treatment.
Case Report (n=3)
Does hydrochlorothiazide improve symptoms in patients with Pseudohypoaldosteronism type II?
Hydrochlorothiazide is an effective treatment for the rare monogenic hypertensive disorder Pseudohypoaldosteronism type II, regardless of the specific underlying genetic mutation.
Objective: Pseudohypoaldosteronism type II is a very rare monogenic hypertensive disorderDesign and method: The typical symptoms are hypertension, hyperkalemia with normal renal function, and metabolic acidosis. There are currently four known disease-causing genes. Results: We reports three patients carrying different mutant genes, with obvious heterogeneity in clinical phenotypes, but all responded to hydrochlorothiazide treatment Conclusions: Clinical screening should be conducted for patients with hypertension combined with hyperkalemia, and long-term follow-up should be provided for confirmed patients
Qian Ge (Fri,) conducted a case report in Pseudohypoaldosteronism type II (n=3). Hydrochlorothiazide was evaluated on Response to treatment. Three patients with pseudohypoaldosteronism type II carrying different mutant genes and exhibiting clinical heterogeneity all responded to hydrochlorothiazide treatment.